[1] World Health Organization.Safety of medicines: a guide to detecting and reporting adverse drug reactions: why health professionals need to take action[R]. World Health Organization, 2002. [2] VAN HUNSEL F, HÄRMARK L, PAL S, et al. Experiences with adverse drug reaction reporting by patients: an 11-country survey[J]. Drug Saf, 2012, 35: 45-60. [3] MARGRAFF F, BERTRAM D.Adverse drug reaction reporting by patients: an overview of fifty countries[J]. Drug Saf, 2014, 37: 409-419. [4] World Health Organization.Safety monitoring of medical products: reporting system for the general public[R/OL]. [2023-04-07].https://www.who.int/. [5] PARRETTA E, RAFANIELLO C, MAGRO L, et al.Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy[J]. Expert Opin Drug Saf, 2014, 13(Suppl 1): S21-S29. [6] BORG JJ, AISLAITNER G, PIROZYNSKI M, et al.Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? a review of the new EU legislation on pharmacovigilance[J].Drug Saf, 2011, 34: 187-197. [7] VARGESSON N.The teratogenic effects of thalidomide on limbs[J]. Journal of Hand Surgery, 2019, 44(1): 88-95. [8] CHAPLIN S.Monitoring drug safety: is the yellow card scheme struggling[J]. Prescriber, 2019, 30(9): 32-34. [9] GILES S.Yellow card scheme reaches 50[J]. Prescriber, 2015, 26(18): 6. [10] NONE. Nurses join yellow card scheme as it goes online[J]. React Wkly, 2002, 927(1): 3. [11] LAWSON DH.The yellow card: mark II[J]. Br J clin Pharmac, 1991, 301: 1234. [12] NONE. Yellow card system given the red card[J]. React Wkly, 1992, 395(4):10 [13] BELTON KJ, LEWIS SC, PAYNE S, et al.Attitudinal survey of adverse drug reaction reporting by medical practitioners in the United Kingdom[J]. Br J clin Pharmac, 1995, 39(3): 223-226. [14] SWEIS D, WONG D.A survey on factors that could affect adverse drug reaction reporting according to hospital pharmacists in Great Britain[J]. Drug Saf, 2000, 23(2): 165-172. [15] HAWCUTT DB, MAINIE P, RIORDAN A, et al.Reported paediatric adverse drug reactions in the UK 2000-2009[J]. Br J clin Pharmac, 2012, 73(3): 437-446. [16] NONE. UK‘yellow card’ADR reporting updated[J]. React Wkly, 2000, 820(1): 2. [17] BLENKINSOPP A, WILKIE P, WANG M, et al.Patient reporting of suspected adverse drug reactions: a review of published literature and international experience[J]. Br J clin Pharmac, 2006, 63(2): 148-156. [18] NONE. Following an independent review of the UK Yellow Card Scheme, the MHRA is to pilot patient reporting[J]. React Wkly, 2004, 1001(1): 21. [19] AVERY AJ, ANDERSON C, BOND CM, et al.Evaluation of patient reporting of adverse drug reactions to the UK ‘Yellow Card Scheme’: literature review, descriptive and qualitative analyses, and questionnaire surveys[J]. Health Technology Assessment, 2011, 15(20): 129. [20] NONE. The yellow card scheme for reporting adverse drug reactions (ADRs) by patients in the UK will complement, not replace, the yellow card reports[J]. React Wkly, 2006, 1109(1): 3. [21] WEBB DJ.An agenda for UK clinical pharmacology: UK medicines policy: the role of clinical pharmacologists[J]. Br J Clin Pharmac, 2012, 73(6): 948-952. [22] Medicines & Healthcare Products Regulatory Agency. Contact us[EB/OL].(2023-08-04)[2023-08-04].https://yellowcard.mhra.gov.uk/contact-us/. [23] WARK S.The Yellow Card Scheme - new reporters including patients, 32nd UK Medicines Information Conference Proceedings[C]. Chester: UK Medicines Information, 2006. [24] NONE. UK yellow card scheme: pharmacists to encourage patient reporting[J]. Pharm Med, 2008, 22(2): 129. [25] INÁCIO P, CAVACO A, ALLAN E, et al. Key pharmacovigilance stakeholders’experiences of direct patient reporting of adverse drug reactions and their prospects of future development in the European Union[J]. Public Health, 2018, 155: 119-128. [26] The Lancet.Improving ADR Reporting[J]. The Lancet, 2002, 360(9344): 1435. [27] KRSKA J, ANDERSON C, MURPHY E, et al.How patient reporters identify adverse drug reactions[J]. Drug Safety, 2011, 34(5): 429-436. [28] Medicines and Healthcare Products Regulatory Agency. Yellow Card Scheme first anniversary for patient reporting - reports from the public up 50%[J]. React Wkly, 2009, 1241(1): 3. [29] WISE J.GPs are urged to report adverse drug reactions after a 37% slump over nine years[J]. BMJ, 2013, 34(feboll): f690. [30] Gov.UK. MHRA Yellow Card Scheme looks to the future at 50th anniversary forum [EB/OL].(2014-11-25)[2023-08-04].https://www.gov.uk/government/news/yellow-card-scheme-looks-to-the-future-at-50th-anniversary-forum. [31] NONE. MHRA reports a milestone: 1 million yellow card reports[J]. React Wkly, 2020, 1830(1): 5. [32] WANG D, REN JT, DONG D, et al.Trend analysis of ten-year annual reports on adverse drug reaction monitoring[J]. Chinese Journal of Pharmocovigilance(中国药物警戒), 2020, 17(5): 276-283. [33] NMPA. NMPA announcement on direct reporting of adverse reactions by drug marketing authorization holders (No. 66, 2018) [EB/OL]. (2018-09-30)[2023-08-01]. https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20180930174301286.html. [34] NMPA. Annual report for national adverse drug reaction monitoring (2020) [EB/OL].(2021-03-26) [2023-08-01]. https://www.cdr-adr.org.cn/center_news/202103/t20210326_48413.html. [35] NMPA. Annual report for national adverse drug reaction monitoring (2021) [EB/OL].(2022-03-30) [2023- 08-01]. https://www.cdr-adr.org.cn/tzgg_home/202203/t20220330_49585.html. [36] MOH. Regulations for the administration of adverse drug reaction reporting and monitoring (No.81, 2011)[ EB/OL]. (2011-05-04)[2023-08-21]. https://www.nmpa.gov.cn/yaopin/ypfgwj/ypfgbmgzh/20110504162501325.html. [37] WANG CG, WANG DF, XU LL, et al.Investigation and reflection on the demand of public reporting of adverse drug reaction in China[J]. Chinese Journal of Pharmocovigilance(中国药物警戒), 2017, 14(7): 402-406. |